S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:AXNX

Axonics - AXNX Stock Forecast, Price & News

$56.04
+0.74 (+1.34%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$55.03
$57.06
50-Day Range
$52.60
$67.34
52-Week Range
$38.41
$79.92
Volume
645,994 shs
Average Volume
701,356 shs
Market Capitalization
$2.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.75

Axonics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
41.0% Upside
$79.00 Price Target
Short Interest
Bearish
7.87% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
1.04mentions of Axonics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$11.94 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

425th out of 989 stocks

Surgical & Medical Instruments Industry

41st out of 99 stocks


AXNX stock logo

About Axonics (NASDAQ:AXNX) Stock

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock News Headlines

The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
When Will Axonics, Inc. (NASDAQ:AXNX) Breakeven?
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Should You Invest in Axonics (AXNX)?
Should You Invest in Axonics (AXNX)?
Why Axonics (AXNX) Surged in the Third Quarter?
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Company Calendar

Last Earnings
3/01/2023
Today
3/24/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
Employees
517
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$69.00
Forecasted Upside/Downside
+42.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-59,700,000.00
Pretax Margin
-22.77%

Debt

Sales & Book Value

Annual Sales
$273.70 million
Book Value
$11.51 per share

Miscellaneous

Free Float
48,810,000
Market Cap
$2.79 billion
Optionable
Not Optionable
Beta
0.41

Key Executives

  • Raymond Wayne CohenRaymond Wayne Cohen
    Chief Executive Officer & Director
  • Danny L. DearenDanny L. Dearen
    President & Chief Financial Officer
  • Rinda K. SamaRinda K. Sama
    Chief Operating Officer
  • Guang Qiang Jiang
    Chief Technology Officer
  • Karen NoblettKaren Noblett
    Chief Medical Officer













AXNX Stock - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price forecast for 2023?

8 brokers have issued 1-year target prices for Axonics' stock. Their AXNX share price forecasts range from $69.00 to $90.00. On average, they predict the company's share price to reach $79.00 in the next year. This suggests a possible upside of 41.5% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2023?

Axonics' stock was trading at $62.53 at the beginning of the year. Since then, AXNX shares have decreased by 10.7% and is now trading at $55.82.
View the best growth stocks for 2023 here
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) posted its earnings results on Wednesday, March, 1st. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.24. The company earned $85.90 million during the quarter, compared to the consensus estimate of $84.14 million. Axonics had a negative trailing twelve-month return on equity of 11.82% and a negative net margin of 21.81%. The company's revenue was up 61.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.34) EPS.

What guidance has Axonics issued on next quarter's earnings?

Axonics updated its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$342.00 million, compared to the consensus revenue estimate of $336.36 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bamco Inc. NY (3.58%), Lord Abbett & CO. LLC (3.37%), Norges Bank (2.47%), Credit Suisse AG (1.94%), Fred Alger Management LLC (1.86%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $55.82.

How much money does Axonics make?

Axonics (NASDAQ:AXNX) has a market capitalization of $2.79 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does Axonics have?

The company employs 517 workers across the globe.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321.

This page (NASDAQ:AXNX) was last updated on 3/24/2023 by MarketBeat.com Staff